In recent trading session, Lineage Cell Therapeutics Inc (AMEX:LCTX) saw 0.72 million shares changing hands at last check today with its beta currently measuring 1.34. Company’s recent per share price level of $1.07 trading at -$0.06 or -5.31% at last check today assigns it a market valuation of $201.73M. That closing price of LCTX’s stock is at a discount of -50.47% from its 52-week high price of $1.61 and is indicating a premium of 21.5% from its 52-week low price of $0.84. Taking a look at company’s average trading volume volume of 929.13K if we extend that period to 3-months.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Upright in the red during last session for losing -5.31%, in the last five days LCTX remained trading in the red while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $1.07 price level, adding 8.55% to its value on the day. Lineage Cell Therapeutics Inc’s shares saw a change of -1.83% in year-to-date performance and have moved -3.60% in past 5-day. Lineage Cell Therapeutics Inc (AMEX:LCTX) showed a performance of -21.32% in past 30-days.
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Statistics highlight that Lineage Cell Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -6.14% of value to its shares in past 6 months, showing an annual growth rate of -33.33% while that of industry is 12.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 95.40% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.36M for the same. And 6 analysts are in estimates of company making revenue of 1.12M in the next quarter. Company posted 2.01M and 3.23M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.25% during past 5 years.
LCTX Dividends
Lineage Cell Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
